Argenx announces fda approval of vyvgart hytrulo for chronic inflammatory demyelinating polyneuropathy

Vyvgart® hytrulo is first and only neonatal fc receptor (fcrn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (cidp)

ARGX Ratings Summary

ARGX Quant Ranking